RFL
NYSERafael Holdings Inc.
Rafael Holdings Inc. (RFL) is a Biotechnology: Pharmaceutical Preparations company listed on NYSE. In the last 30 days Quantisnow tracked 7 wire items for RFL, including 3 press releases and news items, 3 SEC filings and 1 insider trade. The most recent was published Nov 9, 2026.
Financial highlights
Full financials- Revenue, FY2026
- $874.0K
- Revenue growth
- -4.7%
- Net income, FY2026
- -$29.64M
- Net margin
- -3390.7%
- Free cash flow, FY2026
- -$29.99M
- Cash
- $22.10M
For fiscal 2026 (ended Jul 31, 2026), from SEC filings. Not investment advice.
News · 26 weeks20+133%
2026-05-172026-11-08
Mix1090d
- SEC Filings4(40%)
- Other3(30%)
- Insider2(20%)
- Earnings1(10%)
Activity · 52 weeks4328 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNEWARK, N.J., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that it will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on Monday, November 9, 2026 at 3:55 p.m. ET, and host one-on-one meetings with institutional investors. A live webcast can be accessed with this link: https://event.summitcast.com/view/oVDtKqmPn2tPc7VV7WsLAC/ACx7UpLgLXHM3BVo56spTQ. A replay will be available approximately two hours after the completion of the event and will be archived for up to 30 days. About Rafael Holdings, Inc.Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests
- SECSEC Form 10-K filed by Rafael Holdings Inc.10-K - Rafael Holdings, Inc. (0001713863) (Filer)
- SECSEC Form 8-K filed by Rafael Holdings Inc.8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate UpdateNEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the fourth quarter and full fiscal year 2026 ended July 31, 2026. Fiscal 2026 and Recent Corporate Highlights NDA submitted for remibetadex (Trappsol® Cyclo™). On October 28, 2026, Cyclo Therapeutics submitted a New Drug Application (NDA) to the FDA seeking approval of remibetadex for the treatment of Niemann-Pick Disease Type C. The NDA is supported by the Phase 3 TransportNPC™ study, completed in June 2026, which did not meet its primary endpoint in the overall population (p=0.19) but showed 71% slowing of disease progression in a prespecified analysis of patients r
- PRRafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type CNDA supported by the Phase 3 TransportNPC™ study, data from earlier clinical studies, and an overall survival analysis versus external registry controls Remibetadex has received Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA; approval would make remibetadex eligible for a Rare Pediatric Disease Priority Review Voucher United States Adopted Names (USAN) Council assigns nonproprietary name "remibetadex" to Trappsol® Cyclo™ NEWARK, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking
- INSIDERSEC Form 4 filed by Rafael Holdings Inc.4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)Trappsol® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing approximately 83% of the study population, showed a statistically significant effect on the 4DNPCSS Trappsol® Cyclo™ demonstrated a well-tolerated safety and tolerability profile consistent with previous studies, with no new safety signals observed Based upon its previously announced pre-NDA meeting, the Company remains on track to submit the NDA in the fourt
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 2,027 units of Class B Common Stock, decreasing direct ownership by 0.68% to 297,084 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- PRErnexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical StageSeasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026 CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (NASDAQ:ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky to its Board of Directors, further strengthening the Company's leader
- INSIDERExec Chairman, CEO & President Jonas Howard S was granted 54,945 units of Class B Common Stock, increasing direct ownership by 12% to 512,030 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- INSIDERChief Financial Officer Polinsky David covered exercise/tax liability with 2,386 units of Class B Common Stock, decreasing direct ownership by 0.79% to 299,111 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S was granted 142,857 units of Class B Common Stock and covered exercise/tax liability with 8,786 units of Class B Common Stock, increasing direct ownership by 42% to 457,085 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
- SECRafael Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Reports Third Quarter Fiscal 2026 Financial ResultsNEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026. "Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC™ trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need,"
- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type CTopline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC). With 94 patients studied across 27 sites in 13 countries, the TransportNPC™ study is the most comprehensive, cont
- SECRafael Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Rafael Holdings, Inc. (0001713863) (Filer)
- PRRafael Holdings Announces Patent Licensing Agreement with MIT for "Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease"NEWARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today announced that its subsidiary, Cyclo Therapeutics, has entered into an exclusive licensing agreement with Massachusetts Institute of Technology ("MIT") covering U.S. Patent No.12285440. This license covers the use of cyclodextrins in patients with Alzheimer's Disease (AD) who carry an ApoE4 genetic mutation, strengthening the company's intellectual property portfolio around Trappsol® Cyclo™ in this important AD patient population. The ApoE4 gene variant is estimated to be present in 50-70% of patients with AD and is believed to be a key risk factor in the development early onset sporadic AD. Dysregulat
- INSIDERSEC Form 4 filed by Polinsky David4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- INSIDERExec Chairman, CEO & President Jonas Howard S covered exercise/tax liability with 9,826 units of Class B Common Stock, decreasing direct ownership by 3% to 323,014 units (SEC Form 4)4 - Rafael Holdings, Inc. (0001713863) (Issuer)
- SECSEC Form 10-Q filed by Rafael Holdings Inc.10-Q - Rafael Holdings, Inc. (0001713863) (Filer)
RFL FAQ
10 questionsWhat does Rafael Holdings Inc. do?
Rafael Holdings, Inc. owns commercial real estate assets and interests in pre-clinical and clinical stage pharmaceutical companies. The company operates in two segments, Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage; and development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.What is the latest news on RFL?
In the last 30 days Quantisnow tracked 7 wire items for RFL: 3 press releases and news items, 3 SEC filings and 1 insider trade. The most recent was published on November 9, 2026.What is RFL revenue?
Rafael Holdings Inc. (RFL) reported $874.0K of revenue for fiscal 2026 (ended Jul 31, 2026). That is down 4.7% from the year before.Is RFL profitable?
No. Rafael Holdings Inc. reported a net loss of $29.64M for fiscal 2026 (ended Jul 31, 2026).How much cash and debt does RFL have?
Rafael Holdings Inc. reported $22.10M in cash and cash equivalents and $2.0K of debt on its most recent balance sheet in SEC filings.Where does RFL stock trade?
Rafael Holdings Inc. (RFL) is listed on NYSE.What sector and industry is RFL in?
Rafael Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Rafael Holdings Inc. go public?
Rafael Holdings Inc. (RFL) completed its IPO in 2018.What companies are similar to RFL?
Notable peers in the same industry include NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories), MRK (Merck & Company Inc.). Compare RFL side-by-side with any of them on Quantisnow.How can I track RFL on Quantisnow?
Quantisnow aggregates Rafael Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RFL to receive live email and push alerts on every new disclosure.